Theriva Biologics, Inc. (TOVX) Q4 2023 Earnings Call

Investor webinar replay

Replay transcript excerpt

Investor Conference Call. At this time, all participants are in a listen-only mode. As a reminder, this conference is being recorded. I would now like to turn the call over to your host, Chris Calabrese, with LifeSci Advisors. Thank you. You may begin. Thank you, Operator, and good morning, everyone. Welcome to Theriva Biologics' full year of 2023 Investor Conference Call. Leading the call today will be Stephen Shawcross, Chief Executive and Chief Financial Officer of Theriva Biologics. Dr. Manel Cascaio, General Director of Theriva Biologics European Subsidiary, and Dr. Vince Waitcher, Head of Corporate and Product Development of Theriva Biologics, are also on the call and will be available to answer questions during the Q&A session. Theriva Biologics issued a press release this morning, which provided operational highlights and included the financial results for the full year ending December 31st, 2023. The press release can be found in the investor section of the company website at www.ZarivaBio.com, together with the annual report on Form 10-K for full year ended December 31st, 2023, which we plan to file today with the Securities and Exchange Commission. In addition to the phone line, this call is being streamed live via webcast, which will be archived on the company website www.cerevabio.com for 90 days. During this call, certain forward-looking statements regarding Cereva Biologics and DCN Biosciences' current expectations and projections about future events will be made. Generally, the forward-looking statements can be identified by terminology such as may, should, expects, anticipates, intends, plans, believes, estimates, and similar expressions. These statements are based upon current beliefs, expectations, and assumptions, and are subject to a number of ri...